Vertex Medical Equipment company information, Employees & Contact Information

Pharmalittle: We're reading about a GSK drug's comeback, a buyer's club for a Vertex drug, and more statnews.com

(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain Vertex Pharmaceuticals Newsroom

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain Fierce Pharma

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades CNBC

Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence MedCity News

Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval Fox Business

UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary FirstWord Pharma

New Vertex Medication Journavx Approved for Moderate-to-Severe Pain Making Sense of Diabetes

FDA Approves Vertex’s JOURNAVX as First Non-Opioid Acute Pain Reliever Inside Precision Medicine

FDA Approves Non-Opioid Pain Medication Suzetrigine (Journavx™) Yale Medicine

What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades Newsweek

Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia Fierce Pharma

Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med MedCity News

Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease statnews.com

Vertex secures all-star assist for Journavx, signing up NBA's Jayson Tatum for pain drug promotion Fierce Pharma

Promising Vertex Pain Med Points to New Era for Analgesics BioSpace

Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study statnews.com

Medicines | Guidance & Patient Support Vertex Pharmaceuticals

Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study MedCity News

Vertex builds case for non-opioid pain drug ahead of key study readouts BioPharma Dive

‘A game-changer’: How Vertex delivered on cystic fibrosis statnews.com

FDA approves first new non-opioid painkiller in decades, and it's from a MA company. The Patriot Ledger

Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England statnews.com

Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics Fierce Pharma

Vertex Experimental Drug Cuts Off Pain at the Source, Company Says The New York Times

Vertex is hoping for 'historic' non-opioid painkiller approval. It might not be a straightforward blockbuster. The Business Journals

Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline MedCity News

Vertex: non-opioid pain reliever Journavx shows success in post operative pain control 2 Minute Medicine

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX Business Wire

FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain Pharmaceutical Executive

Vertex moves kidney disease drug into late-stage testing BioPharma Dive

Gilead's Yeztugo, Eisai's Leqembi Iqlik, Vertex's Journavx among 2025's best inventions: Time Fierce Pharma

Angry at Vertex pricing of cystic fibrosis drugs, families in four countries seek to override patents statnews.com

'Caught in the middle': A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs statnews.com

Vertex Pharma scientist talks about the long road to developing non-addictive painkillers AP News

Vertex Pharmaceuticals: Humanizing drug discovery Nature

Vertex sinks on reports of deaths of patients taking cystic fibrosis drug statnews.com

Editas cashes in on portion of Vertex gene editing licensing agreement for $57M Fierce Biotech

As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith Fierce Pharma

Vertex gets positive trial results for non-opioid painkiller in boost to pipeline BioPharma Dive

Trailblazing MED Alum to Lead Vertex Pharmaceuticals Boston University

What Is Journavx, the New Opioid-Free Painkiller from Vertex? Scientific American

Vertex's Type 1 diabetes cell therapy heads back to clinic after FDA hold lifted Fierce Biotech

Latigo launches with $135 million for Vertex-competing pain drug statnews.com

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal MedCity News

Selective Inhibition of NaV1.8 with VX-548 for Acute Pain The New England Journal of Medicine

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug The Guardian

Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes MedCity News

Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis Financial Times

Vertex CEO Leiden touts gangbusters Trikafta launch in 'mic drop' earnings call Fierce Pharma

How 3 healthcare organizations are using generative AI blog.google

The Vertex Foundation Gives $1.5 Million to New BU Center for Antiracist Research Boston University

FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years ABC News - Breaking News, Latest News and Videos

FDA approves painkiller designed to eliminate the risk of addiction associated with opioids AP News

AbbVie's cystic fibrosis long-game doesn't pay off, as Galapagos med fails in triple combo Fierce Biotech

Three scientists who revolutionized cystic fibrosis treatment win prestigious Lasker award The Boston Globe

Where Will Vertex Pharmaceuticals Be in 10 Years? The Motley Fool

Vertex wins once-rejected Kalydeco label expansion, bumping guidance by $30M-plus Fierce Pharma

CF fighter Orkambi picks up steam as Vertex forges ahead with VX-661 combos Fierce Pharma

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia The New England Journal of Medicine

Vertex, Concert orchestrate $250M phase 2 CF drug deal Fierce Biotech

Fight not yet over as case against Vertex is dropped after cystic fibrosis medicine price cut spotlightnsp.co.za

Regeneron and Vertex board members rake in highest pay in the S&P 500: Report Fierce Pharma